Nutrien Q2: Record Potash Volumes Drive H1 Beat, Phosphate Catalyst Still Pending

What happened

Nutrien reported Q2 adjusted EBITDA of $2.4 billion, driving first-half EBITDA to $3.5 billion, up 6% year-over-year, fueled by record potash sales volumes and proprietary product margin growth. The results align with the DeepValue report’s base case, validating the 2026 potash volume guidance of 14.1–14.8 million tonnes and Retail EBITDA range of $1.75–$1.95 billion. Operational execution remains strong, but the article omitted any update on the phosphate strategic alternatives review, which management previously committed to finalize in 2026. The stock continues to derive asymmetric upside from potash price torque (±$280 million EBITDA per $25/tonne), yet the phosphate overhang caps a full re-rating. Investor focus should now shift to the pending phosphate decision, as its resolution remains the primary catalyst for unlocking the bull case’s $90 implied value.

Implication

First-half adjusted EBITDA of $3.5 billion, up 6% year-over-year, driven by record potash sales and Retail margin expansion, validates management’s 2026 volume guidance range. This print reduces near-term earnings risk but does not yet address the phosphate strategic alternatives overhang—the key catalyst still expected by year-end. Potash pricing remains the dominant earnings swing factor, with each $25/tonne move shifting EBITDA by ~$280 million; sustained volume strength could be partially offset if pricing weakens from here. Retail’s proprietary product growth and cost discipline provide a buffer against Brazil’s just-in-time buying patterns, supporting the $1.75–$1.95 billion Retail EBITDA guide. Investors should maintain positions but await the phosphate decision before adding; the stock’s upside remains contingent on resolving that segment ahead of the 2026 deadline.

Thesis delta

Nutrien’s Q2 call confirms record potash volumes and proprietary product margin gains, validating the volume and Retail legs of the base case. However, the phosphate strategic review outcome—still the critical catalyst—remains pending, and the stock’s forward return will hinge on management meeting its 2026 deadline to solidify an optimal path.